![](https://investorshub.advfn.com/uicon/297976.png?cb=1610114739)
Tuesday, July 14, 2015 10:51:27 AM
7:00 AM ET 7/14/15 | GlobeNewswire
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive breast cancer, announced today that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting, October 9-12, 2015, at the Washington State Convention Center in Seattle, Washington, USA.
The company will be presenting a responder analysis of the effects of abaloparatide and teriparatide on bone mineral density in postmenopausal women with osteoporosis, the effects of abaloparatide on major osteoporotic fracture incidence as well as pharmacokinetic data from the transdermal patch optimization program. Abstracts summarizing the abaloparatide data are published on the ASBMR website and are available to conference registrants and ASBMR members at: http://www.asbmr.org/ASBMR-abstracts.
Abstracts related to Radius Health include:
Abstract Title: Eighteen Months of Treatment with Abaloparatide Followed by Six Months of Treatment with Alendronate in Postmenopausal Women with Osteoporosis - Results of the ACTIVExtend Trial
Presenter: Felicia Cosman MD, Professor of Clinical Medicine, Columbia University, New York, Clinical Director, National Osteoporosis Foundation
Presentation Number: 1142
Presentation Type: Oral Presentations
Presentation Date/Time: October 12 10:15 AM - 10:30 AM
Session: Plenary Orals: John H. Carsten's Memorial Session: Osteoporosis Session
Session Date/Time: October 12 10:00 AM - 11:30 AM
Room/Details: Room 6 E, Washington State Convention Center
Abstract Title: Response Rates for Hip, Femoral Neck and Lumbar Spine BMD are Higher for Patients Treated with Abaloparatide when Compared to Placebo or Teriparatide - Results of the ACTIVE Trial
Presentation Number: FR0333
Presentation Type: Plenary Sessions
Presentation Date/Time: October 9 5:30 PM - 7:00 PM
Session: Welcome Reception & Plenary Poster Session
Session Date/Time: October 9 5:30 PM - 7:00 PM
Location: Discovery Hall - Hall 4B, Washington State Convention Center
Abstract Title: Effects of Abaloparatide on Major Osteoporotic Fracture Incidence in Postmenopausal Women with Osteoporosis - Results of the Phase 3 ACTIVE Trial
Presentation Number: 1053
Presentation Type: Oral Presentations
Presentation Date/Time: October 10 3:00 PM - 3:15 PM
Session: Concurrent Orals: Osteoporosis Therapy and Management
Session Date/Time: October 10 2:30 PM - 4:00 PM
Location: Hall 4A, Washington State Convention Center
Abstract Title: Transdermal Delivery of Abaloparatide: Optimization of the Pharmacokinetic Profile in Cynomologus Monkeys
Presentation Number: SA0335
Presentation Type: Poster Sessions
Presentation Date/Time: October 10 12:30 PM - 2:30 PM
Session: Poster Session I & Poster Tours
Session Date/Time: 10/10/15 12:30 PM - 2:30 PM
Location: Discovery Hall - Hall 4B, Washington State Convention Center
About the Investigational Drug Abaloparatide
Radius' investigational drug abaloparatide is a synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP), a naturally occurring bone-building hormone that the company believes has the potential to increase bone mineral density by stimulating new bone formation. Abaloparatide-SC is an investigational drug currently completing Phase 3 development for potential use as a daily self-administered injection for the treatment of patients with postmenopausal osteoporosis at high risk of fracture. Radius also is developing the investigational drug abaloparatide-TD for potential use as a short wear-time transdermal patch designed to administer abaloparatide without the need for subcutaneous injection based on 3M's patented Microstructured Transdermal System technology.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, which is completing Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for the treatment of osteoporosis and the investigational drug RAD1901 for the treatment of hormone driven, or hormone resistant, metastatic breast cancer. www.radiuspharm.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our presentations at ASBMR.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our dependence on the success of abaloparatide-SC, and our inability to ensure that abaloparatide-SC will obtain regulatory approval in the timeframe anticipated or at all or be successfully commercialized; we have no product revenues; our need for additional funding, which may not be available; we are not currently profitable and may never become profitable; restrictions imposed on our business by our credit facility, and risks related to default on our obligations under our credit facility; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; risks related to clinical trials, including having most of our products in early stage clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates; product candidates for which we obtain marketing approval, if any, could be subject to restrictions or withdrawal from the market and we may be subject to penalties; failure to achieve market acceptance of our product candidates; risks related to the use of our limited resources on particular product candidates and not others; delays in enrollment of patients in our clinical trials, which could delay or prevent regulatory approvals; the dependence of our drug development program upon third-parties who are outside our control; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide-SC affected the reliability of the data from the study; our reliance on third parties to formulate and manufacture our product candidates; failure to establish additional collaborations; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; developments by competitors may render our products or technologies obsolete or non-competitive; risks related to the fact that our drugs may sell for inadequate prices or patients may be unable to obtain adequate reimbursement; effects of product liability lawsuits on commercialization of our products; failure to comply with obligations of our intellectual property licenses; failure to protect our intellectual property or failure to secure necessary intellectual property related to abaloparatide-SC, abaloparatide-TD, RAD-1901 and/or RAD-140; our or our licensors' inability to obtain and maintain patent protection for technology and products; risks related to our compliance with patent application requirements; failure to protect the confidentiality of our trade secrets; risks related to our infringement of third parties' rights; risks related to employees' disclosure of former employers' trade secrets; risks associated with intellectual property litigation, including expending substantial resources and distracting personnel from their normal responsibilities; risks associated with healthcare reform; our failure to comply with healthcare laws and regulations; our exposure to claims associated with the use of hazardous materials and chemicals; inability to successfully manage our growth; risks relating to business combinations and acquisitions; our reliance on key executive officers and advisors; our inability to hire additional qualified personnel; volatility in the price of our common stock; capital appreciation is the only source of gain for our common stock; risks related to increased costs and compliance initiatives associated with operating as a public company; our directors, executive officers and principal stockholders have substantial control over us and could delay or prevent a change in control; future sales of our common stock could depress the price of our common stock; inaccurate or unfavorable information about us could cause the price of our common stock to decline; provisions in our charter documents and Delaware law could discourage takeover attempts; and our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 10, 2015, and our most recent quarterly and other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
CONTACT: Investor Relations
Barbara Ryan
Clermont Partners
Partner
203-274-2825
bryan@radiuspharm.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxNDE1NjAjMzExNDk=
Recent RDUS News
- Radius Recycling Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 07/02/2024 12:00:00 PM
- Radius Recycling Announces Third Quarter Fiscal 2024 Earnings Date and Webcast Details • GlobeNewswire Inc. • 06/18/2024 09:10:00 PM
- Radius Recycling Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- US Index Futures Rise, Oil Dips Slightly • IH Market News • 04/04/2024 11:31:45 AM
- Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date • GlobeNewswire Inc. • 03/14/2024 08:35:00 PM
- Radius Recycling Named One of the 2024 World’s Most Ethical Companies • Business Wire • 03/04/2024 01:30:00 PM
- Radius Recycling Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 01/04/2024 01:00:00 PM
- Radius Recycling Announces First Quarter Fiscal 2024 Earnings Date and Webcast Details • Business Wire • 12/18/2023 02:00:00 PM
- Radius Recycling Publishes Fiscal Year 2023 Sustainability Report • Business Wire • 12/13/2023 02:15:00 PM
- Radius Recycling Executive Included on TIME100 Climate List of the 100 Most Influential Leaders Driving Business Climate Action • Business Wire • 11/16/2023 01:30:00 PM
- Radius Recycling Reports Fourth Quarter and Fiscal 2023 Financial Results • Business Wire • 10/25/2023 12:00:00 PM
- Radius Recycling Announces Fourth Quarter and Fiscal 2023 Earnings Date and Webcast Details • Business Wire • 09/29/2023 12:30:00 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM